• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, October 20, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

CHLA launches OncoKidsSM – a comprehensive DNA and RNA pediatric cancer panel

Bioengineer by Bioengineer
June 21, 2017
in Science News
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Today, a team of investigators at Children's Hospital Los Angeles launched OncoKidsSM, a next-generation sequencing-based panel specifically designed for pediatric cancers. OncoKidsSM is intended to guide the diagnosis and treatment of a child's cancer based on the genomic alterations specific to the child's tumor. The panel was developed by a team comprised of laboratory geneticists, oncologists and pathologists.

In contrast to adult cancers, which may contain hundreds of sequence alterations, pediatric malignancies may develop from a very small number of mutations, only some of which overlap with the types of mutations seen in adult cancers. Some of these mutations can be present in the germline, and may have been inherited from a parent who may or may not have cancer. Tumor-specific structural changes including duplications, translocations or inversions, which result in novel activating gene fusions, are also much more frequent in childhood cancer than in adult cancer, especially in leukemia and sarcomas.

"We could not simply modify a panel used for adult cancers because the genomic profiles of childhood cancers are so very different," said Timothy Triche, M.D., Ph.D. "OncoKids was designed based on the need we saw in our own clinics, with our own patients."

The OncoKidsSM panel detects mutations, gene amplification and gene fusions for a full range of pediatric cancers including leukemias, bone and soft tissue tumors and brain tumors. The test requires only a small amount of DNA and RNA (20ng) isolated from fresh, frozen or formalin-fixed paraffin-embedded tissue, so that retrospective analysis of primary and recurrent tumors can be performed. The combined DNA and RNA assay can replace many of the single gene, or more narrowly focused, next-generation sequencing-based panels, as well as a variety of fluorescence in situ hybridization assays, which will save time and preserve tissue.

"In addition to providing this unique test panel developed for pediatric cancers, we are also making available our team of experts to provide clinical pathology consultations and to meet with clinical geneticists and genetic counselors in our Cancer Genomics Clinic. These experts can guide patients and physicians with respect to further testing, including germline mutation testing," said Jaclyn Biegel, Ph.D., FACMG, director of the Center for Personalized Medicine at CHLA. "We are also providing clinical investigators and their institutions access to some of the best bioinformatics specialists in the country, who are working on web-based portals for variant curation and data sharing that will be invaluable for both clinical and research applications."

CHLA's Children's Center for Cancer and Blood Diseases is home to one of the largest pediatric hematology-oncology programs in the country.

"For those children whose cancer comes back or does not respond to standard therapy, this advanced genomic analysis can help us determine the next best step. By identifying the specific mutations associated with an individual's cancer, we can better select treatment options that might be most effective," said Alan Wayne, M.D., director of the Children's Center for Cancer and Blood Diseases at CHLA and professor of Pediatrics at the USC Keck School of Medicine and the USC Norris Comprehensive Cancer Center.

###

The OncoKidsSM panel, developed with Thermo Fisher Scientific, uses the Ion Torrent S5 sequencing platform and Ion AmpliSeq technology. Information about OncoKidsSM can be found at http://www.chla.org/chla-oncokids-cancer-panel or requested by emailing [email protected].

About Children's Hospital Los Angeles

Children's Hospital Los Angeles has been named the best children's hospital in California and among the top 10 in the nation for clinical excellence with its selection to the prestigious U.S. News & World Report Honor Roll. Children's Hospital is home to The Saban Research Institute, one of the largest and most productive pediatric research facilities in the United States. Children's Hospital is also one of America's premier teaching hospitals through its affiliation since 1932 with the Keck School of Medicine of the University of Southern California. For more information, visit CHLA.org. Follow us on Twitter, Facebook, YouTube and LinkedIn, or visit our blog at http://researchlablog.org/.

Media Contact

Ellin Kavanagh
[email protected]
323-361-8505
@childrensLA

http://www.childrenshospitalla.org

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Impact of GMAW and SMAW on E350 Steel Properties

October 20, 2025
blank

Unveiling Sex-Switching in Silver Pomfret Juveniles

October 20, 2025

Exploring Motor Differences in Neurodivergence: Initial Insights

October 19, 2025

Innovative Surgical Transfer Sheet: A Randomized Trial

October 19, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1264 shares
    Share 505 Tweet 316
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    296 shares
    Share 118 Tweet 74
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    126 shares
    Share 50 Tweet 32
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    103 shares
    Share 41 Tweet 26

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Impact of GMAW and SMAW on E350 Steel Properties

Unveiling Sex-Switching in Silver Pomfret Juveniles

Exploring Motor Differences in Neurodivergence: Initial Insights

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 65 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.